Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
| Autor: | Thomas Hundsberger, Christophoros Astaras, Andreas F. Hottinger, Bianca Moura, Rita de Micheli |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
business.industry
Mononeuritis Multiplex General Neuroscience medicine.medical_treatment Disease Management Aseptic meningitis Immunotherapy medicine.disease Immunologic activation 03 medical and health sciences Antineoplastic Agents Immunological Autoimmune Diseases of the Nervous System 0302 clinical medicine Immune system Antigen 030220 oncology & carcinogenesis Immunology Humans Medicine Neurology (clinical) business Adverse effect Polyneuropathy 030217 neurology & neurosurgery |
| Zdroj: | Current Neurology and Neuroscience Reports. 18 |
| ISSN: | 1534-6293 1528-4042 |
| Popis: | Immune checkpoint inhibitors represent a major step forward in the field of oncologic immunotherapy these last years and have significantly increased survival of cancer patients in an ever-growing number of indications. These agents block specific immune checkpoint molecules (programmed cell death protein 1 and its ligand as well as cytotoxic T-lymphocyte-associated antigen 4) that normally downregulate the immune response. These new agents show a specific range of adverse effects induced by abnormal immunologic activation. Many different neurologic adverse events have been described, including encephalitis, myelopathy, aseptic meningitis, meningoradiculitis, Guillain-Barre-like syndrome, peripheral neuropathy (including mononeuropathy, mononeuritis multiplex, and polyneuropathy) as well as myasthenic syndrome. Immune checkpoint inhibitors have shown promising results in cancer but can possibly induce autoimmune disorders. Although rare, neurological adverse events require prompt recognition and treatment to avoid substantial morbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink